CVS Health Corp. shares CVS, +1.75% soared 3.8% in premarket trade Wednesday, after the drugstore chain trounced estimates for the second quarter and raised its full-year guidance despite the impact of the coronavirus pandemic on its operations. The company had net income of $2.986 billion, or $2.26 a share, in the quarter, up from $1.931 billion, or $1.49 a share, in the year-earlier period. Adjusted per-share earnings came to $2.64, well ahead of the $1.91 FactSet consensus.
004 billion FactSet consensus. The company said the COVID-19 pandemic adversely affected revenue in the retail and pharmacy services segments, mostly due to fewer new therapy prescriptions due to lower provider visits. Front store revenue was hurt by shelter-in-place orders. CVS raised its full-year EPS guidance and now expects it to range from $5.59 to $5.72, up from a prior range of $5.47 to $5.60. It expects adjusted EPS to range from $7.14 to $7.27 versus a prior range of $7.04 to $7.17.